Oncological characterization of impalpable prostate cancer
Article published in Urologia Polska 2007/60/3.

authors

Jakub Dobruch, Andrzej Borówka, Gerard Grotthuss, Tomasz Dzik, Łukasz Nyk, Piotr Chłosta, Artur A. Antoniewicz: Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej w Warszawie
Dział Urologii Świętokrzyskiego Centrum Onkologii w Kielcach

keywords

prostate, prostate cancer, digital rectal examination, radical prostatectomy

summary

The aim of the study. The authors examined clinical and pathological variables in patients with impalpable prostate cancer (PCa) and compared them with features of patients subjected to radical prostatectomy due to clinically more advanced prostate cancer. Material and method. Charts of all men who underwent radical prostatectomy from January 2001 to December 2006 were analyzed.

Results. Based on histological evaluation of radical prostatectomy specimens, patients who were operated due to impalpable prostate cancer were more likely to have organ confined and more differentiated PCa than patients with abnormal digital rectal examination (DRE). Respective rates of organ confined and Gleason score less than 7 PCa are 56%, 66% and 52%, 57%. Patients who were subjected to RP due to impalpable and invisible PCa were also charactarized by lower rates of extracapsular extension and Gleason score more than 6 prostate cancer in comparison to the rest of the patients.

Conclusions. Radical prostatectomy performed in men due to impalpable cancer is associated with favorable outcome. Additionally men with impalpable and invisible prostate cancer constitute the low risk group of patients.

references

http://85.128.14.124/krn (28.02.2007).
Dobruch J, Borówka A, Antoniewicz AA, Chłosta P: Epidemiology of prostate cancer: changes observed in Poland in 1991-2000. Urol Pol 2005, 58, 26-30.
Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998, 52, 444-448.
Paquette EL, Sun L, Paquette LR et al: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002, 60, 756-759.
Schröder FH, Hennanek P, Denis L et al: The TNM classification of prostate cancer. Prostate 1992, suppl. 4, 129.
Dobruch J, Borówka A: Lead time w badaniach przesiewowych majšcych na celu wczesne rozpoznanie raka stercza. Przeg Urol 2004, 5, 4, 20-23.
Dobruch J, Borówka A: Uwagi na temat raka stercza nieistotnego klinicznie. Przeg Urol 2005, 32, 57-59.
Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage Tlc) prostate cancer. JAMA 1994, 271, 368-374.
Humphrey PA, Keetch DE, Smith DS et al: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996, 155, 816-820.
Veltri RW, Miller CM, Mangold LA et al: Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. J Urol 2002, 168, 100-104.
Gretzer MB, Epstein JI, Pond CR et al: Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. Urology 2002 60, 1034-1039.
Aus G, Abbou CC, Bolla M et al: EAU Guidelines on Prostate Cancer 2006, 1-106.
Flemming ID, Cooper JS, Hemson DE et al: American Joint Committee on Cancer Staging Manual, 5-e wyd. Philadelphia, JP Lippincott 1997, 219-222.
Ellis WJ, Chetner MP, Preston SD et al: Diagnosis of prostatic carcinoma: the yield of serum prostate-specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994, 152, 1520-1525.
Flanigan RC, Catalona WJ, Richie JP et al: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994, 152, 1506-1509.
Smith JA Jr, Scardino PT, Resnick MI et al: Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: Results of a prospective, multi-institutional trial. J Urol 1997, 157, 902-906.
Dobruch J, Modzelewska E, Popiel M et al: Stopień klinicznego zaawansowania raka stercza w momencie rozpoznania. Urol Pol 2006, 59, 269-274.
Stamey TA, Donaldson AN, Yemoto CE et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. Journal of Urology 1998, 160, 2412-2417.
Ung JO, Richie JP, Chen MH et al: Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002, 60, 458-463.
Postma R, Leenders GJLH, Roobol MJ et al: Tumor features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006, 50, 70-75.
Partin AW, Kattan MW, Subong EN et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277, 1445-1451.
Grossklaus DJ, Coffey CS, Shappell SB et al: Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 2002, 167, 2032-2036.
Sebo TJ, Bock BJ, Cheville JC et al: The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000, 163, 174-178.
Augustin H, Graefen M, Palisaar J et al: Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging. J Urol 2003, 21, 2860-2868.
Tiguert R, Gheiler EL, Grignon DJ et al: Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors. J Urol 2000, 163, 1486-1490.
Ohori M, Wheeler TM and Scardino PT: The new American Joint Committee on Cancer and International Union against Cancer TNM classification of prostate cancer: clinicopathologic correlations. Cancer 1994, 74, 104-114.
Ohori M, Kattan MW, Utsunomiya T et al: Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible? J Urol 2003, 169, 964-968.

correspondence